At a glance
ClinicalIndex Comparison RecordN/ACompleted· 163 enrolled
Drug / intervention
Revanesse Ultra +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra Versus Restylane® for the Correction of Nasolabial Folds
In Brief
A clinical study evaluating Revanesse Ultra and Restylane for Nasolabial Fold Correction. Completed, enrolled 163 participants.
Detailed Summary
A randomized, multicenter, double blind, split-face study in subjects seeking NLF correction. Subjects were treated with Revanesse Ultra in the NLF on one side of the face and Restylane in the NLF on the other side of the face. The side of the face for each product was randomly assigned. The investigator performing the evaluations and the subject were blinded to the treatment; injections of the study product were performed by an unblinded injecting investigator.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasolabial Fold Correction
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
Primary CompletionMar 2016
Study CompletionSep 2016
First PostedDec 2016
TodayJul 2026
First PostedDec 8, 2016
Enrollment StartMay 1, 2015
Primary CompletionMar 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.6 years ago
Interventions
Revanesse Ultradevice
NLF correction
Restylanedevice
NLF Correction